In vitro replication capacity of HIV-2 variants from long-term aviremic individuals (Q56880140)

0 references

author name string

Hetty Blaak

0 references

Marchina E. van der Ende

0 references

Patrick H.M. Boers

0 references

Hanneke Schuitemaker

Replicative capacity of HIV-2, like HIV-1, correlates with severity of immunodeficiency.

0 references

language of work or name

English

0 references

publication date

September 2006

0 references

published in

Virology

0 references

volume

353

0 references

issue

0 references

page(s)

144-154

0 references

cites work

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2006.05.029

The replicative fitness of primary human immunodeficiency virus type 1 (HIV-1) group M, HIV-1 group O, and HIV-2 isolates

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2006.05.029

Low level viremia and high CD4% predict normal survival in a cohort of HIV type-2-infected villagers

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2006.05.029

In vitro replication kinetics of human immunodeficiency virus type 1 (HIV-1) variants in relation to virus load in long-term survivors of HIV-1 infection

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2006.05.029

HIV-2-infected individuals with undetectable plasma viremia carry replication-competent virus in peripheral blood lymphocytes

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2006.05.029

CCR5, GPR15, and CXCR6 are major coreceptors of human immunodeficiency virus type 2 variants isolated from individuals with and without plasma viremia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2006.05.029

Individual contributions of mutant protease and reverse transcriptase to viral infectivity, replication, and protein maturation of antiretroviral drug-resistant human immunodeficiency virus type 1.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2006.05.029

pol gene sequence variation in Swedish HIV-2 patients failing antiretroviral therapy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2006.05.029

Relationship between in vitro human immunodeficiency virus type 1 replication rate and virus load in plasma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2006.05.029

Virologic and immunologic characterization of long-term survivors of human immunodeficiency virus type 1 infection

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2006.05.029

Biologic heterogeneity of human immunodeficiency virus type 2 (HIV-2) strains

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2006.05.029

Polymorphism and drug-selected mutations in the reverse transcriptase gene of HIV-2 from patients living in southeastern France

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2006.05.029

Plasma RNA viral load in human immunodeficiency virus type 2 subtype A and subtype B infections

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2006.05.029

High frequency of selection of K65R and Q151M mutations in HIV-2 infected patients receiving nucleoside reverse transcriptase inhibitors containing regimen

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2006.05.029

CD8+ T cell responses to human immunodeficiency viruses type 2 (HIV-2) and type 1 (HIV-1) gag proteins are distinguishable by magnitude and breadth but not cellular phenotype

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2006.05.029

Equal plasma viral loads predict a similar rate of CD4+ T cell decline in human immunodeficiency virus (HIV) type 1- and HIV-2-infected individuals from Senegal, West Africa

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2006.05.029

No differences in cellular immune responses between asymptomatic HIV type 1- and type 2-infected Gambian patients

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2006.05.029

Declining HIV-2 prevalence and incidence among men in a community study from Guinea-Bissau

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2006.05.029

Human immunodeficiency virus types 1 and 2 have different replication kinetics in human primary macrophage culture.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2006.05.029

Lessons from the second AIDS virus, HIV-2.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2006.05.029

Reduced rate of disease development after HIV-2 infection as compared to HIV-1

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2006.05.029

Relationships between infectious titer, capsid protein levels, and reverse transcriptase activities of diverse human immunodeficiency virus type 1 isolates

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2006.05.029

HIV-1 dynamics in vivo: virion clearance rate, infected cell life-span, and viral generation time

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2006.05.029

Centrifugal enhancement of human immunodeficiency virus (HIV) and human herpesvirus type 6 (HHV-6) infection in vitro

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2006.05.029

Lower human immunodeficiency virus (HIV) type 2 viral load reflects the difference in pathogenicity of HIV-1 and HIV-2.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2006.05.029

Prevalence of and mortality from human immunodeficiency virus type 2 in Bissau, West Africa

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2006.05.029

9-year HIV-2-associated mortality in an urban community in Bissau, west Africa

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2006.05.029

Risk factors for HIV-2 seropositivity among older people in Guinea-Bissau. A search for the early history of HIV-2 infection

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2006.05.029

A dual infection/competition assay shows a correlation between ex vivo human immunodeficiency virus type 1 fitness and disease progression

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2006.05.029

The effects of HIV-2 infection in a rural area of Guinea-Bissau.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2006.05.029

Differences in disease progression in a cohort of long-term non-progressors after more than 16 years of HIV-1 infection

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2006.05.029

Cytotoxic T lymphocyte responses to human immunodeficiency virus: control and escape.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2006.05.029

Limiting dilution assays. Experimental design and statistical analysis.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2006.05.029

CD8+ T cell mediated noncytolytic inhibition of human immunodeficiency virus type I.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2006.05.029

HIV-2-infected patients survive longer than HIV-1-infected patients.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2006.05.029

Neutralizing antibodies mechanism of neutralization and protective activity against HIV-1.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2006.05.029

Comparison of human immunodeficiency virus (HIV)-specific T-cell responses in HIV-1- and HIV-2-infected individuals in Senegal.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2006.05.029